NCT06492304View on ClinicalTrials.gov

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

May 31, 2030

Study Completion Date

November 30, 2030

Conditions
T Cell LymphomaB Cell LymphomaAcute Myeloid Leukemia
Interventions
BIOLOGICAL

CTX131

CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components

Trial Locations (7)

3002

RECRUITING

Research Site 7, East Melbourne

10065

RECRUITING

Research Site 4, New York

10467

RECRUITING

Research Site 2, The Bronx

77030

RECRUITING

Research Site 1, Houston

85054

RECRUITING

Research Site 6, Phoenix

94305

RECRUITING

Research Site 5, Stanford

02114

RECRUITING

Research Site 3, Boston

Sponsors
All Listed Sponsors
lead

CRISPR Therapeutics

INDUSTRY